<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/837BAF8D-D113-4776-8C2C-1AD63DD26B27"><gtr:id>837BAF8D-D113-4776-8C2C-1AD63DD26B27</gtr:id><gtr:name>Catsci Ltd</gtr:name><gtr:address><gtr:line1>CBTC2 CAPITAL BUSINESS PARK , WENTLOOG</gtr:line1><gtr:city>CARDIFF</gtr:city><gtr:postCode>CF3 2PX</gtr:postCode><gtr:region>Wales</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/837BAF8D-D113-4776-8C2C-1AD63DD26B27" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>837BAF8D-D113-4776-8C2C-1AD63DD26B27</gtr:id><gtr:name>Catsci Ltd</gtr:name><gtr:address><gtr:line1>CBTC2 CAPITAL BUSINESS PARK , WENTLOOG</gtr:line1><gtr:city>CARDIFF</gtr:city><gtr:postCode>CF3 2PX</gtr:postCode><gtr:region>Wales</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>68134.0</gtr:offerGrant><gtr:projectCost>90846.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B6ABECD8-EB0D-4075-A052-678522AAC8A9" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>B6ABECD8-EB0D-4075-A052-678522AAC8A9</gtr:id><gtr:name>Shasun Pharma Solutions Limited</gtr:name><gtr:address><gtr:line1>DUDLEY , CRAMLINGTON</gtr:line1><gtr:city>NORTHUMBERLAND</gtr:city><gtr:postCode>NE23 7QG</gtr:postCode><gtr:region>North East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>51996.0</gtr:offerGrant><gtr:projectCost>79994.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F147BD27-7F0C-4ECA-96D1-57C429B623C8" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>F147BD27-7F0C-4ECA-96D1-57C429B623C8</gtr:id><gtr:name>Prozomix Limited</gtr:name><gtr:address><gtr:line1>Unit 3 
Station Court
Haltwhistle</gtr:line1><gtr:city>Northumberland</gtr:city><gtr:postCode>NE49 9HN</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>54602.0</gtr:offerGrant><gtr:projectCost>72802.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A20E93AB-C252-4174-B1F6-54856058C583"><gtr:id>A20E93AB-C252-4174-B1F6-54856058C583</gtr:id><gtr:firstName>Jonathan</gtr:firstName><gtr:surname>Moseley</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=131914"><gtr:id>F6B1C3F7-8914-44B4-B3E5-E378195B252E</gtr:id><gtr:title>Alternative synthesis of huperzine A with keto-reductases</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Feasibility Studies</gtr:grantCategory><gtr:grantReference>131914</gtr:grantReference><gtr:abstractText>A consortium comprising Shasun, Prozomix and CatScI has been established as part of the Innovate UK?s IB Catalyst. The key goal of the project is to develop a novel IB route to a nutraceutical that is currently manufactured through traditional chemical manufacturing techniques or isolated from scarce natural resources. The new technology has the potential to significantly reduce manufacturing costs whilst concomitantly allowing an increased output of the nutraceutical with a more robust supply chain. Additionally, this will have the added benefits of generating a more sustainable process as it will be more energy efficient and less reliant on hydrocarbon and precious metal based technologies. A successful project will allow the consortium to compete with manufacture in low-cost economies and help ensure that production of this critical nutraceutical continues in the United Kingdom.</gtr:abstractText><gtr:fund><gtr:end>2016-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2015-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>174732</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">131914</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>